Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCAT | P04180 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 1/20 | 0.31 |
| ▸ | MLYCD | O95822 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3880244 | 0.95 | LCAT (0.33) | LCATTACR3 | |
| SCHEMBL3880002 | 0.86 | PARP1 (0.36) | LCATMLYCD | |
| SCHEMBL3881400 | 0.86 | PIK3CG (0.32) | MLYCD | |
| SCHEMBL3879718 | 0.84 | NOS1 (0.40) | — | |
| SCHEMBL3880697 | 0.84 | HRH3 (0.39) | LCAT | |
| SCHEMBL3880463 | 0.82 | MLYCD (0.34) | MLYCD | |
| SCHEMBL3879086 | 0.82 | PIK3CG (0.32) | — | |
| SCHEMBL3880495 | 0.81 | HRH3 (0.39) | MLYCD | |
| SCHEMBL3881737 | 0.81 | CHRNB2 (0.39) | LCAT | |
| SCHEMBL3882089 | 0.80 | PARP1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | claimed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | claimed |
| EP-1858900-B1 | FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR | GLAXO GROUP LTD (GB) | 2009-01-07 | — | — | EP | disclosed |
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | GLAXO GROUP LIMITED | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161289-A1 | Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor | HRH3, HRH4, HRH2 | LCAT 3120/4885AOC3 893/4885TACR3 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.